These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 29704874)

  • 1. The convergence theory for vitiligo: A reappraisal.
    Kundu RV; Mhlaba JM; Rangel SM; Le Poole IC
    Exp Dermatol; 2019 Jun; 28(6):647-655. PubMed ID: 29704874
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitiligo and the Role of Newer Therapeutic Modalities.
    Nimkar P; Wanjari A
    Cureus; 2022 Nov; 14(11):e31022. PubMed ID: 36475210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical appraisal of vitiligo etiologic theories. Is melanocyte loss a melanocytorrhagy?
    Gauthier Y; Cario Andre M; Taïeb A
    Pigment Cell Res; 2003 Aug; 16(4):322-32. PubMed ID: 12859615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Review of the etiopathomechanism of vitiligo: a convergence theory.
    Le Poole IC; Das PK; van den Wijngaard RM; Bos JD; Westerhof W
    Exp Dermatol; 1993 Aug; 2(4):145-53. PubMed ID: 8162332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vitiligo, from Pathogenesis to Therapeutic Advances: State of the Art.
    Diotallevi F; Gioacchini H; De Simoni E; Marani A; Candelora M; Paolinelli M; Molinelli E; Offidani A; Simonetti O
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.
    van den Boorn JG; Konijnenberg D; Dellemijn TA; van der Veen JP; Bos JD; Melief CJ; Vyth-Dreese FA; Luiten RM
    J Invest Dermatol; 2009 Sep; 129(9):2220-32. PubMed ID: 19242513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vitiligo: where do we stand?
    Ortonne JP; Bose SK
    Pigment Cell Res; 1993 Mar; 6(2):61-72. PubMed ID: 8321867
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autoimmune aspects of vitiligo.
    Kemp EH; Waterman EA; Weetman AP
    Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetics of generalized vitiligo.
    Spritz RA
    Curr Dir Autoimmun; 2008; 10():244-57. PubMed ID: 18460890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanocyte destruction and repigmentation in vitiligo: a model for nerve cell damage and regrowth.
    Yu HS
    J Biomed Sci; 2002; 9(6 Pt 2):564-73. PubMed ID: 12432222
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autoimmune diseases affecting skin melanocytes in dogs, cats and horses: vitiligo and the uveodermatological syndrome: a comprehensive review.
    Tham HL; Linder KE; Olivry T
    BMC Vet Res; 2019 Jul; 15(1):251. PubMed ID: 31324191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo. Pathogenesis and treatment.
    Njoo MD; Westerhof W
    Am J Clin Dermatol; 2001; 2(3):167-81. PubMed ID: 11705094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New insights into immune mechanisms of vitiligo.
    Boniface K; Taïeb A; Seneschal J
    G Ital Dermatol Venereol; 2016 Feb; 151(1):44-54. PubMed ID: 26512930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuro-immuno-endocrine processes in vitiligo pathogenesis.
    Miniati A; Weng Z; Zhang B; Stratigos AJ; Nicolaidou E; Theoharides TC
    Int J Immunopathol Pharmacol; 2012; 25(1):1-7. PubMed ID: 22507311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Role of Memory CD8
    Riding RL; Harris JE
    J Immunol; 2019 Jul; 203(1):11-19. PubMed ID: 31209143
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vitiligo at the sites of irradiation in a patient with Hodgkin's disease.
    Pajonk F; Weissenberger C; Witucki G; Henke M
    Strahlenther Onkol; 2002 Mar; 178(3):159-62. PubMed ID: 11962193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The melanocytorrhagic hypothesis of vitiligo tested on pigmented, stressed, reconstructed epidermis.
    Cario-André M; Pain C; Gauthier Y; Taïeb A
    Pigment Cell Res; 2007 Oct; 20(5):385-93. PubMed ID: 17850512
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vitiligo: a manifestation of apoptosis?
    Huang CL; Nordlund JJ; Boissy R
    Am J Clin Dermatol; 2002; 3(5):301-8. PubMed ID: 12069635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CCL22 to Activate Treg Migration and Suppress Depigmentation in Vitiligo.
    Eby JM; Kang HK; Tully ST; Bindeman WE; Peiffer DS; Chatterjee S; Mehrotra S; Le Poole IC
    J Invest Dermatol; 2015 Jun; 135(6):1574-1580. PubMed ID: 25634358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melanocytorrhagy and apoptosis in vitiligo: connecting jigsaw pieces.
    Kumar R; Parsad D
    Indian J Dermatol Venereol Leprol; 2012; 78(1):19-23. PubMed ID: 22199056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.